ALSO NOTED: Teva loses out on Celebrex copycat; Wyeth to build $280M plant in China;

> Switzerland's Cytos stirred up some excitement with its announcement that new trial data backs up its hopes for a new vaccine that can be used to thwart high blood pressure. Report

> A federal appeals court tossed out one of Pfizer's three patents on the painkiller Celebrex, but upheld a lower court's decision that ruled out a copycat version from Teva Pharmaceutical Industries because it would infringe on the remaining two. The ruling would keep Teva's generic off the market till 2015. Report | Report

> Wyeth plans to spend $280 million to build a plant in China that will make mostly infant formula and nutritional products for the regional market; when complete in 2010, it's expected to employ 300. Release

> Immunicon plans to cut 45 of its 100 workers after a dispute over the marketing of its CellSearch cancer test with Veridex, a Johnson & Johnson unit. Report

> Eleven drug makers have agreed to pay $125 million over average wholesale prices after a lawsuit charged that consumers and payors paid more than they should have because of false reporting. The new settlement includes Abbot, Amgen, Sanofi-Aventis, Baxter, Bayer, and others. Report

> The FDA gave its nod for Spectrum Pharmaceuticals' oncology drug Levoleucovorin; the company expects to launch by June. Report

> Cepheid is cashing in on MRSA trends--for now. Report

And Finally... Who keeps drug-sample inventories and rides herd on departing sales reps? Sports trainers. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.